Suppr超能文献

knockdown 抑制肝癌细胞的增殖、侵袭和转移,并增强它们对 TRAIL 诱导的细胞凋亡的敏感性。

Knockdown Inhibits the Proliferation, Invasiveness, and Metastasis of Hepatocellular Carcinoma Cells and Sensitizes them to TRAIL-Induced Apoptosis.

机构信息

Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Department of General Surgery, First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi 030001, China.

出版信息

Chin Med J (Engl). 2018 Oct 5;131(19):2320-2331. doi: 10.4103/0366-6999.241800.

Abstract

BACKGROUND

XB130 is a recently discovered adaptor protein that is highly expressed in many malignant tumors, but few studies have investigated its role in hepatocellular carcinoma (HCC). Therefore, this study explored the relationship between this protein and liver cancer and investigated its molecular mechanism of action.

METHODS

The expression of XB130 between HCC tissues and adjacent nontumor tissues was compared by real-time polymerase chain reaction, immunochemistry, and Western blotting. XB130 silencing was performed using small hairpin RNA. The effect of silencing XB130 was examined using Cell Counting Kit-8, colony assay, wound healing assay, and cell cycle analysis.

RESULTS

We found that XB130 was highly expressed in HCC tissues (cancer tissues vs. adjacent tissues: 0.23 ± 0.02 vs. 0.17 ± 0.02, P < 0.05) and liver cancer cell lines, particularly MHCC97H and HepG2 (MHCC97H and HepG2 vs. normal liver cell line LO-2: 2.35 ± 0.26 and 2.04 ± 0.04 vs. 1.00 ± 0.04, respectively, all P < 0.05). The Cell Counting Kit-8 assay, colony formation assay, and xenograft model in nude mice showed that silencing XB130 inhibited cell proliferative ability both in vivo and in vitro, with flow cytometry demonstrating that the cells were arrested in the G0/G1 phase in HepG2 (HepG2 XB130-silenced group [shA] vs. HepG2 scramble group [NA]: 74.32 ± 5.86% vs. 60.21 ± 3.07%, P < 0.05) and that the number of G2/M phase cells was decreased (HepG2 shA vs. HepG2 NA: 8.06 ± 2.41% vs. 18.36 ± 4.42%, P < 0.05). Furthermore, the cell invasion and migration abilities were impaired, and the levels of the epithelial-mesenchymal transition-related indicators vimentin and N-cadherin were decreased, although the level of E-cadherin was increased after silencing XB130. Western blotting showed that the levels of phosphorylated phosphoinositide 3-kinase (PI3K) and phospho-protein kinase B (p-Akt) also increased, although the level of phosphorylated phosphatase and tensin homolog increased, indicating that XB130 activated the PI3K/Akt pathway. Furthermore, we found that a reduction in XB130 increased liver cancer cell sensitivity to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

CONCLUSIONS

Our findings suggest that XB130 might be used as a predictor of liver cancer as well as one of the targets for its treatment.

摘要

背景

XB130 是一种最近发现的衔接蛋白,在许多恶性肿瘤中高表达,但很少有研究探讨其在肝细胞癌(HCC)中的作用。因此,本研究探讨了这种蛋白与肝癌的关系,并研究了其作用的分子机制。

方法

采用实时聚合酶链反应、免疫化学和 Western blot 比较 HCC 组织和相邻非肿瘤组织中 XB130 的表达。使用短发夹 RNA 沉默 XB130。通过细胞计数试剂盒-8 检测、集落形成实验、划痕愈合实验和细胞周期分析来检测沉默 XB130 的效果。

结果

我们发现 XB130 在 HCC 组织(癌组织与相邻组织:0.23±0.02 与 0.17±0.02,P<0.05)和肝癌细胞系,尤其是 MHCC97H 和 HepG2 中高表达(MHCC97H 和 HepG2 与正常肝细胞系 LO-2:2.35±0.26 和 2.04±0.04 与 1.00±0.04,均 P<0.05)。细胞计数试剂盒-8 检测、集落形成实验和裸鼠异种移植模型表明,沉默 XB130 可抑制体内外细胞的增殖能力,流式细胞术显示 HepG2 细胞被阻滞在 G0/G1 期(HepG2 XB130 沉默组 [shA]与 HepG2 乱序组 [NA]:74.32±5.86%与 60.21±3.07%,P<0.05),G2/M 期细胞数量减少(HepG2 shA 与 HepG2 NA:8.06±2.41%与 18.36±4.42%,P<0.05)。此外,细胞侵袭和迁移能力受损,上皮-间充质转化相关指标波形蛋白和 N-钙黏蛋白的水平降低,而沉默 XB130 后上皮钙黏蛋白水平升高。Western blot 显示,磷酸化磷脂酰肌醇 3-激酶(PI3K)和磷酸化蛋白激酶 B(p-Akt)的水平也升高,尽管磷酸化磷酸酶和张力蛋白同源物的水平升高,表明 XB130 激活了 PI3K/Akt 通路。此外,我们发现 XB130 的减少增加了肝癌细胞对肿瘤坏死因子相关凋亡诱导配体诱导的凋亡的敏感性。

结论

我们的研究结果表明,XB130 可能可作为肝癌的预测指标之一,也可能成为其治疗的靶点之一。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b668/6166462/f890f14d24d6/CMJ-131-2320-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验